Data Sheet 1: Pediatric Phase I/II Trial of Durvalumab and Tremelimumab

A figshare-hosted document details a phase I/II clinical trial evaluating the combination of durvalumab and tremelimumab in pediatric patients with advanced solid tumors. The study, authored by Darren Hargrave, includes results from 50 total patients across dose-finding and dose-expansion phases, assessing safety, pharmacokinetics, and antitumor activity. The document was last updated in May 2026.

Use Cases

• Analyzing safety profiles of combination immunotherapy based on reported treatment-related adverse events in 76% of patients
• Evaluating antitumor activity in pediatric sarcomas based on the reported lack of objective responses
• Studying immune cell activation in response to therapy based on reported increases in CD4+Ki67+ T cells
• Determining recommended pediatric dosing based on pharmacokinetic data from the dose-finding phase

Strengths

• Includes results from a specific clinical trial with 50 total pediatric patients
• Reports specific dosing regimens (D 30 mg/kg + T 1 mg/kg) and response metrics like partial response duration (10.8 months)
• Provides detailed safety data, including grade 3 or 4 adverse event rates (19%)

Limitations

• Dataset is a single 507.9 KB DOCX file; row and column structure are unknown
• Column-level documentation is absent; field semantics must be inferred after download
• Data may reflect the specific patient population and trial design bias inherent to the source

Provenance

Source

Darren Hargrave via figshare

Collection Method

Clinical trial data collection as part of a phase I/II study

Freshness

Last updated 2026-05-15 04:21:42; freshness should be verified